Vor Biopharma (VOR) News Today → “Retirement Secret” Showed 995% Gain Last Time We Shared It (From Stansberry Research) (Ad) Free VOR Stock Alerts $1.70 -0.04 (-2.30%) (As of 04/25/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial MediaStock AnalysisAnalyst ForecastsChartEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineVor Biopharma (NYSE:VOR) Receives Outperform Rating from Wedbushamericanbankingnews.com - April 24 at 5:20 AMVor Biopharma (NYSE:VOR) Earns "Outperform" Rating from Wedbushmarketbeat.com - April 23 at 1:48 PMVor Biopharma (NYSE:VOR) Trading Down 5.3%americanbankingnews.com - April 16 at 1:52 AMBuy Rating Affirmed for Vor Biopharma on Clinical Progress and Market Potentialmarkets.businessinsider.com - April 13 at 12:43 AMVor Bio to Participate in Upcoming Investor Conferencesglobenewswire.com - April 1 at 8:00 AMHere's Why We're Watching Vor Biopharma's (NASDAQ:VOR) Cash Burn Situationfinance.yahoo.com - March 29 at 7:12 AMThe Penny Stock A-List: 7 High-Profile Companies on the Verge of Greatnessinvestorplace.com - March 28 at 2:28 PMStifel Nicolaus Sticks to Its Buy Rating for Vor Biopharma (VOR)markets.businessinsider.com - March 26 at 1:44 AMAnalysts Offer Insights on Healthcare Companies: TELA Bio (TELA) and Vor Biopharma (VOR)markets.businessinsider.com - March 22 at 3:59 PMVor Biopharma's (VOR) Market Outperform Rating Reaffirmed at JMP Securitiesmarketbeat.com - March 22 at 2:11 PMVor Biopharma Inc. Expected to Post Q1 2025 Earnings of ($0.24) Per Share (NYSE:VOR)marketbeat.com - March 22 at 8:35 AMVor Biopharma: Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Updatefinanznachrichten.de - March 22 at 5:21 AMAnalysts Have Conflicting Sentiments on These Healthcare Companies: LivaNova (LIVN), Vor Biopharma (VOR) and Neurogene (NGNE)markets.businessinsider.com - March 21 at 7:20 PMVor Biopharma (NYSE:VOR) Price Target Cut to $12.00 by Analysts at Stifel Nicolausmarketbeat.com - March 21 at 10:56 AMOppenheimer Reaffirms "Outperform" Rating for Vor Biopharma (NYSE:VOR)marketbeat.com - March 21 at 9:38 AMVor Biopharma: Q4 Earnings Insightsbenzinga.com - March 20 at 9:49 PMVor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Updatefinance.yahoo.com - March 20 at 4:49 PMVor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Updateglobenewswire.com - March 20 at 4:05 PMVor Biopharma (VOR) to Release Quarterly Earnings on Thursdaymarketbeat.com - March 20 at 7:46 AMIntellia Therapeutics doses first patient in pivotal in vivo CRISPR trialmsn.com - March 19 at 5:15 PMVOR Apr 2024 5.000 callfinance.yahoo.com - March 16 at 11:47 PMVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - March 5 at 4:01 PMVor Bio to Participate in Upcoming Investor Conferencesglobenewswire.com - March 4 at 8:00 AMInstitutions own 36% of Vor Biopharma Inc. (NASDAQ:VOR) shares but private equity firms control 43% of the companyfinance.yahoo.com - February 17 at 9:46 AM2 “Strong Buy” Penny Stocks That Could Rally All the Way to $10 (or More)finance.yahoo.com - February 15 at 5:49 PMVor Bio to Participate in the Oppenheimer 34th Annual Healthcare Life Sciences Conferencefinance.yahoo.com - February 7 at 4:09 PMPersonnel changes in the Exyte management: Mark Garvey and Elena Bashkeeva are welcomed as new members of the Executive Boardfinanznachrichten.de - February 5 at 12:31 PMVaxart spikes as B. Riley upgrades at long last after BARDA fundingmsn.com - January 31 at 7:57 PMVor Biopharma's (VOR) "Outperform" Rating Reiterated at Wedbushmarketbeat.com - January 18 at 8:43 AMVor Biopharma: Vor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Updatefinanznachrichten.de - January 18 at 8:31 AMVor Bio Doses First AML Patient with VCAR33 (ALLO) and Provides Corporate Updatefinance.yahoo.com - January 17 at 5:56 PMBuy Rating Justified by CRISPR Therapeutics’ Strong Pipeline and Market Potentialmarkets.businessinsider.com - January 9 at 8:42 PMVor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of "Buy" by Analystsmarketbeat.com - December 14 at 1:30 AMVor Bio Presents Positive Data Update on Trem-cel at HSCT² Conferencefinance.yahoo.com - November 9 at 8:20 PMVor Biopharma: Vor Bio Reports Third Quarter 2023 Financial Results and Provides Company Updatefinanznachrichten.de - November 8 at 7:42 AMVor Biopharma GAAP EPS of -$0.49 misses by $0.02msn.com - November 7 at 9:41 PMVor Bio Reports Third Quarter 2023 Financial Results and Provides Company Updatefinance.yahoo.com - November 7 at 9:41 PMPositive Clinical Updates and Promising Engraftment Data Bolster Buy Rating for Vor Biopharmamarkets.businessinsider.com - November 6 at 6:48 PMPositive Clinical Trials and Promising Future: Reaffirming Buy Rating for Vor Biopharmamarkets.businessinsider.com - November 4 at 1:42 PMMultiple Clinical and Preclinical Presentations at ASH 2023 Highlight Vor Bio’s Novel eHSC and CAR-T Platformfinance.yahoo.com - November 2 at 1:42 PMVor Biopharma (VOR) Price Target Increased by 8.55% to 15.75msn.com - October 4 at 11:34 PMVor Biopharma: Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)finanznachrichten.de - October 4 at 8:32 AMVor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)finance.yahoo.com - October 3 at 8:40 PMBaker BROS. Advisors LP Trims Stock Position in Vor Biopharma Inc. (NYSE:VOR)marketbeat.com - September 12 at 5:41 AMJonesTrading Initiates a Buy Rating on Prime Medicine, Inc. (PRME)markets.businessinsider.com - September 5 at 8:38 PMVor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of "Buy" by Brokeragesmarketbeat.com - September 5 at 2:16 AMVor Biopharma (NASDAQ: VOR)fool.com - August 16 at 9:02 PMJMP Securities Reiterates Vor Biopharma (VOR) Market Outperform Recommendationmsn.com - August 14 at 4:20 PMThe Latest Analyst Ratings for Vor Biopharmamarkets.businessinsider.com - August 14 at 4:20 PMRA Capital Management, L.P. Increases Stake in Vor Biopharma Inc.gurufocus.com - August 12 at 5:04 AM Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address “Retirement Secret” Showed 995% Gain Last Time We Shared It (Ad)Central Banks Buying Gold in Record Numbers Most folks have completely missed the fact that the world's Central Banks have been quietly gobbling up as much gold as they can… Stacking it in their locked vaults on pallets in record numbers. Find out why right here (and see what you can do to get in too with just a few dollars). VOR Media Mentions By Week VOR Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. VOR News Sentiment▼0.260.37▲Average Medical News Sentiment VOR News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. VOR Articles This Week▼31▲VOR Articles Average Week Get Vor Biopharma News Delivered to You Automatically Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: NGM News Today FTLF News Today OMGA News Today GTH News Today OM News Today BHG News Today VTGN News Today CRDL News Today ANVS News Today KPTI News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NYSE:VOR) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchBetter than Bitcoin? The Biotech Stock with 46,751% PotentialBehind the MarketsExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersI’m afraid WWIII is a very real possibility Porter & CompanyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill Publishing Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vor Biopharma Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
